The European Medicines Agency (EMA) has recommended the approval of Pfizer's respiratory syncytial virus (RSV) vaccine, Abrysvo, for adults aged 60 years and older. This marks a significant step in expanding preventive options for a population at increased risk of severe RSV-related illness.

RSV is a common respiratory virus that can cause serious complications in older adults, including pneumonia and exacerbations of chronic conditions. The EMA's recommendation is based on clinical trial data demonstrating the vaccine's efficacy and safety profile in reducing the incidence of lower respiratory tract disease caused by RSV.

Pending final approval by the European Commission, Abrysvo could become one of the first RSV vaccines available for older adults in Europe. Healthcare professionals are encouraged to stay informed about upcoming guidance on vaccine administration and eligibility criteria.